

Adult CIRB - Early Phase Emphasis Meeting Agenda

September 17, 2024

I Amendment

10572, A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-related Inhibitor M1774 (Version Date 07/30/24)

II Continuing Review

10490, Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide (Version Date 09/12/23)

III Continuing Review

10528, A Phase 1 Study of the Polymerase Theta (POL θ) Inhibitor Novobiocin in BRCA-mutant and Other DNA Damage Repair-Deficient Solid Tumors (Version Date 04/16/24)

IV Continuing Review

10608, A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma (Version Date 08/09/24)
